As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
HOME > BUSINESS
BUSINESS
- PeptiDream, JCR to Collaborate to Discover Peptide-Drug Conjugates that Pass Through Blood-Brain Barrier
February 24, 2016
- Zosyn Generics Face Labeling Revisions, Shipment Halts over False-Positive Concerns
February 23, 2016
- Shionogi’s Naldemedine Yields Positive PIII Results for Opioid-Induced Constipation
February 23, 2016
- Fuso’s Voluntary Recall Escalated to Order-Based Recall
February 23, 2016
- Israel’s Pluristem in Hunt for Japan Partner to Market Placenta-Based Cell Therapies
February 22, 2016
- Merck Serono Likely to Halt Serophene Sales in Japan, Notification Sent Out to Medical Societies
February 22, 2016
- Sanofi Suffers 6.6% Decline in Japan Revenues
February 22, 2016
- Fuso Voluntarily Recalls Maltose-Lactated Ringer’s Inj. and Replas Injection Due to Mislabeling
February 22, 2016
- Ferring Revs Up for Full-Fledged Foray into GI Market, Eyes Japan Sales of €300 Million in 2020
February 19, 2016
- Fujifilm Begins US PI Study for Cancer Drug FF-10502
February 19, 2016
- Sakigake: Now and Future (3) - Astellas’s FLT3 Inhibitor for AML Receives Designation, but Other Companies Trailing
February 19, 2016
- US Merck to Sell Daiichi Sankyo’s Lixiana in 13 European Countries
February 18, 2016
- JCR to Roll Out Cell Therapy Temcell on Feb. 24; Medipal to Be Exclusive Distributor
February 18, 2016
- Genzyme Japan to Be Merged into Sanofi in July
February 17, 2016
- Eisai, Sysmex Link Up in Next-Gen Diagnostic Reagents for Dementia
February 16, 2016
- Shionogi Joins Cambridge Therapeutic Consortium
February 16, 2016
- Asahi Kasei, Pfizer Wind Up Recomodulin Copromotion Scheme
February 16, 2016
- Otsuka’s Pharma Sales Down Nearly 15% in 2015
February 15, 2016
- Pfizer’s Metformin 500 mg Fails to Clear Test, Shipment Suspended
February 15, 2016
- Astellas Completes Acquisition of Ocata
February 15, 2016
ページ
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…